BriaCell Therapeutics +$0.02 +9.04% Friday 15:00
1D 1W 1M 3M 1Y 5Y
14 Jun Confirmed
This list is based on the watchlists of people on Stock Events who follow BCTXW. It's not an investment recommendation.
This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer is involved in developing cancer immunotherapies, directly competing with BriaCell's focus on advanced breast cancer treatments.
Merck's strong presence in the oncology sector, especially with its blockbuster drug Keytruda, makes it a direct competitor in cancer treatment. Bristol-Myers Squibb
BMY
Mkt Cap 86.44B
Bristol Myers Squibb has a robust lineup of cancer drugs and is actively involved in developing immunotherapies, competing in the same space as BriaCell. Gilead Sciences
GILD
Mkt Cap 90.4B
Gilead Sciences, with its acquisition of Kite Pharma, has become a key player in the cancer immunotherapy market, competing with BriaCell's therapies. Novartis
NVS
Mkt Cap 232.42B
Novartis is a major pharmaceutical company with a strong emphasis on oncology, including breast cancer treatments, making it a competitor.
Amgen's focus on innovative treatments for cancer places it in direct competition with BriaCell, especially in the development of biologics.
Roche, through its Genentech division, is a leader in cancer therapeutics, including breast cancer, competing with BriaCell's targeted approach. Astrazeneca
AZN
Mkt Cap 244.04B
AstraZeneca has a significant portfolio in oncology, including breast cancer treatments, making it a competitor in the same therapeutic area as BriaCell. Regeneron Pharmaceuticals
REGN
Mkt Cap 114.81B
Regeneron Pharmaceuticals' work in developing monoclonal antibodies for cancer treatment puts it in competition with BriaCell's immunotherapy approach. Iovance Biotherapeutics
IOVA
Mkt Cap 2.23B
Iovance Biotherapeutics focuses on T-cell-based therapies for cancer, competing in the innovative immunotherapy space alongside BriaCell.
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Show more...